Drug News
A new study explores the use of psilocybin, a 5HT2AR agonist, as an adjunct in smoking cessation treatment
Drug News
Method: Data were analyzed for participants (n = 683) of a randomized controlled trial comparing the efficacy of different smoking cessation pharmacotherapies (Wisconsin, 2005–2008). Activity (assessed via pedometry) and body weight were measured in the days surrounding the quit day and again one year later, at which time 7-day point-prevalence abstinence from smoking was assessed.